Zhi Tong Cai Jing·2025-12-23 02:11Core Viewpoint - Rongchang Biologics (09995) has seen a stock increase of over 3%, currently at 78.8 HKD, with a trading volume of 98.38 million HKD, following the release of promising clinical trial data for its PD-1/VEGF bispecific antibody RC148 [1] Group 1: Clinical Research and Development - According to Huaxi Securities (002926), the clinical research data for RC148, both as a monotherapy and in combination therapy for non-small cell lung cancer (NSCLC), has demonstrated outstanding clinical efficacy and manageable safety [1] - The early data from the RC148-C001 study has led to the drug receiving Breakthrough Therapy Designation (BTD) in China for the treatment of locally advanced or metastatic NSCLC that has failed prior PD-1/PD-L1 inhibitors and platinum-based chemotherapy [1] - The company is actively advancing its clinical trials, with the Phase II trial for RC148 in combination therapy for first-line NSCLC having completed patient enrollment and plans to initiate a Phase III clinical study [1]